Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is a single arm phase II study of adjuvant intra-dermal NA DC vaccine combined with
intravenous nivolumab in patients with resectable HCC (group A) or CRLM (group B) planned for
curative surgery (with/without local ablation).